Generic Drugs Market - Global Competitive Analysis
Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1084
Competitive Analysis - Top 10 generic drug manufacturers, in terms of revenue, in 2016, are as follows:
TEVA PHARMACEUTICAL INDUSTRIES
NOVARTIS INTERNATIONAL AG
Teva Pharmaceuticals Industries strengthened its position in the generic drugs market through acquisition of the generic segment of Allergan, plc for US$ 40.5 billion in August 2016. This resulted in significant growth in revenue contribution of its generic drug segment, pegged at US$ 9.5 billion in 2016.
Mylan ranks second in the list of generic drug manufacturers, and this is due to the acquisition valued at US$ 7.2 Bn of Sweden’s Meda by Mylan, in year 2016. This also aided Mylan to increase its sales of over-the-counter drugs and expand its presence in new emerging markets such as China, Southeast Asia, Russia, and the Middle East.
Sandoz—Novartis Group’s business segment dealing in generic medicines—reported rampant growth of 9% Y-o-Y in 2016, in sales volume, with revenue pegged at US$ 9 Bn. However, it was partially offset by a 6% erosion in price. Pfizer is at the fourth position (US$ 4.6 Bn revenue in 2016). Pfizer acquired Hospira in 2015, in order to increase its product portfolio of both generic and branded products. Pfizer offers over 220 injectable medications, plus other off-brand products, which is expected to aid in gaining high revenue in near future. Patent loss of Viagra in 2017, will lead to significant generic competition from Teva and Mylan.
Allergan though ranked at fifth position, sold its generics assets to Teva in 2015, and the deal closed in August 2016, which takes the company out of the race for generic drug manufactures for 2017, till the company receives new approval for generic drug manufacturing. This can favor Aspen Pharma to enter the top 10 generic drug manufacturers league in 2017. Sun Pharmaceuticals Ltd., headquartered in Mumbai, India, generated over US$ 3.6 Bn in generic sales in 2016. Sun Pharmaceutical doubled its size by the acquisition of Ranbaxy Laboratories in 2015, thus expanding its product portfolio. However, growth was hampered when the FDA issued a warning letter in 2015 for the Halol, India, API plant, which supplies the generic products in the U.S. Owing to this, Sun Pharmaceuticals is unable to receive new generic drug approvals.
Fresunius Kabi, a generic arm of the Fresenius German Healthcare Group, reported a 4% growth in revenue from the U.S. in 2016 driven by strong sales of sterile injectable drugs. In 2017, the company entered into agreement to buy Akorn—a generic drugs manufacturer—for US$ 4.5 Bn, further strengthening its position in the market. For Endo Pharmaceuticals, till 2014, the generic segment did not generate significant revenue. However, following its acquisition of Par Pharmaceutical in 2015, revenue of Endo Pharmaceutical increased by 12.2% from 2012-2014. Following the acquisition, Endo enhanced its product portfolio with the addition of around 100 products, which also included profitable generic products.
Lupin, in 2016, completed acquisition of U.S.-based Gavis and obtained its first manufacturing site in the U.S., along with 60 ANDA filings pending approval with the FDA. This aided the company to increase its footprint in the highly lucrative U.S. market.
Access Table of Content (TOC) Of the Report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1084
Increase in number of competitor’s for generic drugs market put the pressure on manufacturers of pricing. Moreover, price celling actions by respective governments is further aggravating the profit margins of generic drug manufacturers. Considering the challenges of pricing pressure as generics outfits feel the pinch with thin margins, the market is expected to exhibit steady growth in the future.
Being a very lucrative market with a number of patent expires in the near future, it is essential for competitive analysis for market players. This could aid one in devising a unique strategy and process to sustain in this highly competitive generic drugs market.
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Generic Drugs Market - Global Competitive Analysis here
News-ID: 1203880 • Views: 352
More Releases from Coherent Market Insights
Emergency Lighting Battery Market- Comprehensive Study Explores Huge Growth in F …
Emergency lights are battery operated lighting devices that can automatically light emergency exit signs during power outage, in order to maintain continuous operation of the emergency light such as emergency escape lighting and standby lighting among others, to enable all occupants to evacuate the premises safely during an emergency situation. The key features of emergency lights includes low maintenance costs where only the periodic test and general cleaning are required
Electronic Nose Market : Get Details like Top Industry Players | Technology | In …
An electronic nose is a device used for sensing smell, odors, and fragrance of the surrounding. This device consists of electronic sensing, which is used for comparison, identification, quantification, and even data storage and recovery. Electronic noses comprises three primary elements: a delivery system, a discovery system, and a calculating system. These electronic nose offers commercial advantages over the human equivalent. For example, for companies handling large-scale production activities,
Smart Sensors Market to Witness Robust Expansion with Key Competitors Rockwell A …
A smart sensor is a device that takes input from the physical environment and uses built-in compute resources to perform predefined functions upon detection of specific input and then process data before passing it on. Smart sensors are used for digital processing i.e. it converts the analog signal to digital. Thus, it can be used across verticals such as consumer electronics, automotive, industrial, medical, security & defence, and entertainment. Increasing sales
Power Distribution Unit Market | Industry Size, Share, Future Trends With Emergi …
Power distribution unit (also known as main distribution unit) is an electronic device, which is designed to distribute and manage electricity supply, computer, and network devices. Increasing volume of data is one of the major factors leading to high demand for data centers, which is in turn fueling growth of the power distribution unit market. According to Coherent Market Insights' analysis, the number of hyper scale data center was 259
More Releases for Pharma
Global Deferasirox Market 2018 - Novartis, Cipla, Sun Pharma, Natco Pharma
Apex Market Reports, recently published a detailed market research study focused on the “Deferasirox Market” across the global, regional and country level. The report provides 360° analysis of “Deferasirox Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Deferasirox on the basis of
Big Pharma Outlook 2026
Boston, MA ReportsWorldwide has announced the addition of a new report title Big Pharma Outlook 2026 to its growing collection of premium market research reports. Pharmavitae Analytics casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals at a low single-digit compound annual growth rate (CAGR) of 0.9%. Using in-house sales forecasts,
Clomifene Citrate Market 2017 - Sanofi, Palam Pharma, Bioxera, Zafax Pharma
Apex Research, recently published a detailed market research study focused on the "Clomifene Citrate Market" across the global, regional and country level. The report provides 360° analysis of "Clomifene Citrate Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Clomifene Citrate industry, and estimates the future trend of Clomifene Citrate market on
12th World Pharma Congress
Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting in an abundant knowledge of the mechanisms driving drug discovery and development. Pharmaceutical Formulation Market size was USD $147billion in 2015 and is anticipated to reach around USD 175.1 billion by 2018. In USA, the total number of new drugs approved between
12th World Pharma Congress
Conference Series has taken an initiation to conduct International Pharma Congress worldwide. From several years Conference Series has been conducting Pharma Congress conferences in major continents like Europe, America and Asia Pacific. Previous conferences were held in city like USA, with success. Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting
4th African Pharma Congress
In the light of this theme, the conference series aims to provide a forum for international researchers from various areas of pharmaceutical sciences like chemical processing, industrial practice, analytical methods and pharmacological actions by providing a platform for critical analysis of new agenda, and to share latest cutting-edge research findings and results about all aspects of Pharmacy We are honoured to invite pharmacists, researchers, professors, scientific communities, delegates, students, business